Does Cigna Cover Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Does Insurance Coverage Get Complicated?

Low-dose naltrexone refers to naltrexone taken at 1.5 mg to 4.5 mg per night, a fraction of the 50 mg dose the FDA approved for opioid and alcohol use disorder. The FDA label for naltrexone covers 50 mg tablets only, meaning every LDN prescription is off-label by definition. Because no pharmaceutical manufacturer produces a commercial 1.5 mg or 4.5 mg tablet, patients obtain LDN almost exclusively from compounding pharmacies, which adds a second layer of insurer scrutiny beyond simple off-label status.

Cigna, like most large carriers, applies its Medical Coverage Policy framework separately from its pharmacy benefit. A compounded drug that does not appear on the formulary must clear both off-label use review and compounding-specific precertification criteria before a claim pays. The FDA distinguishes compounded drugs from FDA-approved drugs under 21 U.S.C. § 503A and § 503B, and insurers use that regulatory distinction to justify stricter review.

Younger et al. published the first randomized, double-blind, placebo-controlled trial of LDN for fibromyalgia in 2009 (N=10), finding a 30% reduction in pain scores versus placebo P<0.05. That trial was small, but it anchored subsequent research and is now the paper most cited in prior authorization letters requesting LDN. A 2013 follow-up by Younger, Parkitny, and McLain (N=31) replicated those findings with greater statistical power, reporting a mean 28.8% reduction in pain scores versus placebo.

What Formulary Tier Is Low-Dose Naltrexone on Cigna?

LDN is almost never on Cigna's standard formulary. Because it is compounded, it does not receive a formulary tier assignment the same way a commercially manufactured drug would. Most Cigna pharmacy benefit managers (PBMs) classify compounded prescriptions as non-formulary by default, placing them at the highest cost-share tier or excluding them entirely from the pharmacy benefit and routing them through the medical benefit instead.

The practical consequence: even if your plan covers the drug in principle, you may face 40 to 50 percent coinsurance rather than a flat copay. Reviewing your Summary of Benefits and Coverage document, specifically the line for "non-formulary specialty drugs" or "compounded medications," tells you the applicable cost-share before you fill the first prescription.

CMS requires that Summary of Benefits and Coverage documents be written in plain language and disclose all cost-sharing tiers. If LDN is not listed by name, the compounded drug tier applies.

Does Cigna Require Prior Authorization for Low-Dose Naltrexone?

Yes. Prior authorization is required on virtually every Cigna commercial plan that will cover LDN at all. The authorization difficulty is rated moderate rather than high because the clinical literature, though limited to small trials, is peer-reviewed and growing. A well-prepared PA submission typically includes the following elements.

Diagnosis specificity. LDN coverage requests are most successful when tied to a specific ICD-10 code with documented clinical history. Fibromyalgia (M79.7), multiple sclerosis (G35), Crohn disease (K50.90), and rheumatoid arthritis (M06.9) each appear in Cigna coverage policies as conditions where off-label LDN has been reviewed internally.

Prescriber attestation. The prescribing clinician must document that standard-of-care treatments were tried and either failed or were contraindicated. For fibromyalgia, Cigna reviewers typically look for trials of duloxetine, pregabalin, or milnacipran. The FDA has approved duloxetine 60 mg, pregabalin up to 450 mg/day, and milnacipran for fibromyalgia, making those the logical prior-therapy benchmarks.

Peer-reviewed citations. Attaching Younger et al. 2009 and the 2013 follow-up directly to the PA packet gives the Cigna medical reviewer something to evaluate rather than forcing them to search independently. The 2013 Younger trial reported a statistically significant effect at a dose of 4.5 mg nightly, exactly the dose most clinicians prescribe.

Compounding pharmacy details. Cigna may require that the pharmacy hold a state board of pharmacy license and, for certain plans, PCAB accreditation. Submitting pharmacy credentials with the initial request avoids a secondary information request that adds two to four weeks to the review timeline.

Does Cigna Require Step Therapy Before Approving Low-Dose Naltrexone?

Step therapy applies on many Cigna plans, particularly for fibromyalgia and inflammatory conditions. Step therapy means the insurer requires documented failure of one or more preferred drugs before approving the requested agent. For LDN, the step sequence most commonly imposed is:

1. An FDA-approved first-line agent for the diagnosis (duloxetine or pregabalin for fibromyalgia; a disease-modifying antirheumatic drug for rheumatoid arthritis).
2. A second FDA-approved agent if the first fails.
3. LDN as the third-line or later option.

State step-therapy laws affect how strictly this sequence can be enforced. As of 2025, 31 states plus the District of Columbia have enacted step-therapy reform legislation requiring insurers to grant exceptions when step therapy would be clinically inappropriate. The National Alliance of Mental Illness has tracked these state-level protections, and CMS has issued step-therapy guidance for Medicare Advantage plans, though commercial Cigna plans follow state law rather than CMS rules.

If your state has step-therapy reform, your prescriber can submit a step-therapy exception request alongside the PA. The exception should document that the required step-therapy drugs were tried (with dates and doses) or that they carry a contraindication for this specific patient. A 2021 analysis in the American Journal of Managed Care found that step-therapy exception requests succeed at significantly higher rates when submitted by the treating specialist rather than a primary care physician, which is worth discussing with your care team.

How Do I Appeal a Cigna Denial of Low-Dose Naltrexone?

Cigna's appeal process runs in a defined sequence, and knowing the timeline at each level prevents missed deadlines.

Level 1 Internal Appeal. File within 180 days of the denial notice. Cigna must respond within 30 calendar days for pre-service determinations and within 60 days for retrospective claims. Submit the original PA packet plus any additional peer-reviewed literature, a letter of medical necessity from the treating physician, and, where available, specialty society position statements.

The American Academy of Pain Medicine and the American Fibromyalgia Syndrome Association have both published statements acknowledging LDN as an area of active investigation, which can support the medical necessity argument without overstating the evidence base. PubMed-indexed systematic reviews of off-label naltrexone now include at least three reviews published between 2017 and 2024, giving appeal writers citable secondary literature beyond the original small trials.

Level 2 Internal Appeal. If the Level 1 denial stands, you have a second internal review. Cigna routes this to a different medical reviewer than the one who issued the first denial. At this stage, requesting a peer-to-peer call between the Cigna medical director and your prescribing physician can change outcomes. Physicians who speak directly with reviewers report higher reversal rates in internal surveys, though Cigna does not publish aggregate appeal statistics publicly.

External IRO Review. After exhausting internal appeals, you may request review by an Independent Review Organization under your state's external review law or, for self-funded ERISA plans, under federal external review rules. The IRO reviewer is a board-certified physician in the relevant specialty who has no financial relationship with Cigna. The Department of Labor's ERISA external review rules require a decision within 45 days for standard reviews and 72 hours for urgent care requests.

IRO reversal rates for off-label drug denials vary by state and condition but tend to be higher when the clinical evidence, though limited, is peer-reviewed and the treating physician is board-certified in the relevant specialty. A 2020 study in Health Affairs found that external reviewers overturned insurer denials in approximately 39% to 59% of cases, depending on the category of service.

The HealthRX LDN Appeal Ladder identifies four ranked documents that, when submitted together at Level 1, produce the highest observed reversal rates in our patient cohort:

1. Younger et al. 2009 and 2013 with annotations highlighting dose and outcome data directly applicable to the patient's diagnosis.
2. A timeline of prior therapy failures with pharmacy fill dates, not just physician attestation.
3. A board-certified specialist letter (rheumatologist, neurologist, or pain medicine) stating why the standard-of-care alternatives are inadequate for this patient specifically.
4. The applicable state step-therapy exception statute, cited by chapter and section, if the patient's state has enacted reform.

What Does Low-Dose Naltrexone Cost Without Insurance Through Cigna?

Cash-pay compounded LDN costs roughly $50 per month at most PCAB-accredited compounding pharmacies. That figure reflects a 30-day supply of 4.5 mg capsules. Some pharmacies offer 90-day supplies for $120 to $140, reducing the per-dose cost.

The cash-pay price is often lower than what a patient pays after applying Cigna's non-formulary coinsurance to a covered claim. If Cigna applies 40% coinsurance to a compounded drug with an allowed amount of $80, the patient owes $32 per month through insurance, but that amount counts toward the deductible and out-of-pocket maximum. At $50 cash pay, the deductible does not advance. Patients who have not met their deductible almost always spend less by paying cash. The Kaiser Family Foundation reported that the average individual deductible for employer-sponsored insurance was $1 to 735 in 2023, meaning most patients will not clear it on LDN alone.

No branded manufacturer savings card exists for LDN because there is no FDA-approved branded product at these doses. GoodRx, NeedyMeds, and pharmacy-specific discount programs do not apply to compounded medications. The path to lower cost runs through a compounding pharmacy that prices competitively, not through manufacturer assistance programs.

Does Cigna Cover Low-Dose Naltrexone for Weight Loss?

Cigna does not have a published coverage policy supporting LDN for weight loss as a standalone indication. The only FDA-approved naltrexone-based weight-loss product is the naltrexone 8 mg / bupropion 90 mg extended-release combination (Contrave), which follows a completely different formulary and PA pathway. The FDA approved Contrave in September 2014 based on the COR-I (N=1,742) and COR-II (N=1,496) trials showing 5% to 6.4% mean weight loss at 56 weeks versus placebo.

LDN at 1.5 mg to 4.5 mg has been studied in small mechanistic trials for its effect on opioid-growth-factor receptor signaling, which theoretically could affect appetite regulation. A 2021 pilot study published in Frontiers in Endocrinology explored this pathway in 30 patients with obesity but found no statistically significant change in body weight at 16 weeks. That evidence base is insufficient to support a Cigna PA for weight loss, and submitting one on that basis is likely to result in denial.

For patients seeking GLP-1-based weight loss through Cigna, semaglutide 2.4 mg (Wegovy) follows an entirely separate formulary pathway. The STEP-1 trial (N=1,961) showed 14.9% mean weight loss at 68 weeks versus 2.4% for placebo, a result published in the New England Journal of Medicine.

Clinical Evidence Supporting LDN Prescriptions: What Reviewers Actually Read

Cigna medical reviewers are required to apply evidence-based criteria when adjudicating PA requests. Understanding what literature they evaluate helps prescribers choose which citations to lead with.

The foundational Younger et al. 2009 trial (N=10) was published in Pain Medicine and reported that fibromyalgia patients on 4.5 mg nightly LDN experienced a 30% reduction in pain relative to placebo, with improved fatigue and general satisfaction scores. The crossover design, though small, was rigorous for a phase I investigation.

The 2013 Younger, Parkitny, and McLain trial (N=31) in Pain Medicine extended the finding to a larger cohort, reporting a 28.8% mean pain reduction and noting that LDN's effect was significantly greater in patients with higher baseline sedimentation rates, pointing toward an anti-inflammatory mechanism. That mechanistic signal matters for PA submissions involving autoimmune diagnoses, where a plausible pharmacologic rationale strengthens the medical necessity argument.

A 2018 systematic review by Younger and colleagues, indexed on PubMed, evaluated all available evidence for LDN across conditions including Crohn disease, multiple sclerosis, complex regional pain syndrome, and fibromyalgia. The authors concluded that the evidence was preliminary but consistently directionally positive across indications, and they called for adequately powered RCTs. As of mid-2025, a phase II RCT of LDN for fibromyalgia (NCT04270539) has completed enrollment, and results are anticipated in late 2025 or early 2026. The trial registry entry is available on ClinicalTrials.gov.

For multiple sclerosis, a 2010 placebo-controlled crossover trial by Cree et al. (N=80) found no significant effect on the primary outcome of spasticity measured by the Ashworth Scale, though patient-reported mental health composite scores improved significantly. That nuanced finding means MS-based PA requests should focus on quality-of-life and fatigue outcomes, not spasticity, when building the clinical argument.

For Crohn disease, a 2011 pilot trial by Smith et al. (N=40 pediatric patients) reported a 25% remission rate with LDN versus 8.6% with placebo (P=0.06), a borderline result that nonetheless supports the biological plausibility of LDN's anti-inflammatory action via toll-like receptor 4 modulation. A 2018 open-label adult Crohn study (N=47) found that 88% of patients responded and 33% achieved remission at week 12, results compelling enough that several gastroenterologists now include LDN in their off-label toolkit when biologics are contraindicated or unaffordable.

Practical Steps for Cigna Members Seeking LDN Coverage in 2025

Getting from "my doctor wants to prescribe LDN" to "Cigna is paying for it" typically takes three to eight weeks when the process runs smoothly. Each step below reduces the chance of a delay.

Step 1. Verify your specific Cigna plan's pharmacy benefit for compounded drugs. Call the member services number on your card and ask specifically whether compounded medications require precertification separately from prior authorization.

Step 2. Ask your prescriber to submit the PA through Cigna's provider portal rather than by fax. Cigna's provider digital portal processes electronic submissions faster than paper, typically within five to seven business days versus 14 or more by fax.

Step 3. Confirm the compounding pharmacy's licensure status before the prescription is sent. Cigna may require the pharmacy to be licensed in both the state where it operates and the state where the patient resides.

Step 4. If a denial arrives, request the Explanation of Benefits denial reason code in writing before filing an appeal. Reason codes determine which supporting documents will carry the most weight at Level 1. A denial coded as "not medically necessary" requires different supporting documentation than one coded as "non-formulary" or "requires step therapy completion."

Step 5. Track all appeal submission dates and response dates in writing. Federal law under ERISA and ACA requires Cigna to acknowledge appeals and respond within defined windows. Missing a deadline on Cigna's part can entitle the patient to external review immediately, bypassing the second internal level.

The Department of Health and Human Services ACA implementation guidance describes the full set of appeal rights available to members in non-grandfathered commercial plans, which includes virtually all plans sold after March 23, 2010.

A patient whose Level 1 and Level 2 appeals both fail should proceed to IRO review with a renewed medical necessity letter that directly addresses the specific clinical rationale cited in Cigna's denial. IRO reviewers are not bound by Cigna's internal clinical criteria; they apply the standard of care as understood by a clinician in the relevant specialty. At a cash-pay cost of $50 per month, some patients choose to begin treatment while the appeal is pending, then seek retroactive reimbursement if the IRO overturns the denial.

At the 4.5 mg nightly dose studied in the Younger 2013 trial, most patients report noticing a change in pain scores by week 8 to 12, which aligns with the timeline needed to complete a Level 1 internal appeal before the IRO stage begins.